Although the prevalence of distal sensory peripheral neuropathy decreased following initiation of cART in people living with in resource-limiting settings, better strategies are needed.
Peripheral nervous system disease is a component of systemic lupus erythematosus disease activity and has a significant negative impact on health-related quality of life.
A Prescription Drug User Fee Act (PDUFA) target date of July 13, 2020 has been assigned to the application.
Higher systolic blood pressure and decreased low-density lipoprotein are associated with increased risk for peripheral neuropathy in patients with type 2 diabetes.
Although the prevalence of distal sensory peripheral neuropathy decreased following initiation of cART in people living with in resource-limiting settings, better strategies are needed.
Amphiphysin-IgG-mediated autoimmunity is an important clinical entity characterized by neuropathy.
When traditional oral analgesics no longer control pain, some physicians are turning to alternative drug delivery methods that provide pain relief while avoiding systemic adverse effects.
There is limited evidence supporting the efficacy of cannabis for refractory chronic pain, including chronic neuropathic pain.
CNTX-6016, a highly-selective cannabinoid receptor type 2 agonist, was found to provide adequate analgesia in preclinical models of neuropathic pain.
Recognition of the wide phenotype spectrum in immune checkpoint inhibitor-related neuropathy and prompt management with corticosteroids may lead to favorable outcomes.
